Repligen delivered Q4 2025 revenue of 197913000 dollars, up 18% year-over-year, with GAAP net income of 13287000 dollars compared to a loss in the prior year. Gross margin expanded significantly and operating income turned positive, reflecting strong execution and operating leverage.

Repligen posted 22% revenue growth in Q3 2025 driven by strength across all franchises and geographies. Gross and operating margins improved, and EPS turned positive with strong adjusted results.

Repligen delivered a solid second quarter in 2025, achieving 15% revenue growth and 17% organic non-COVID revenue growth. The company improved gross profit, operating income, and earnings per share year-over-year, while also raising its full-year guidance.

Repligen had a strong start to 2025 with $169 million in revenue, representing 14% organic non-COVID growth, and a significant increase in adjusted operating income. Total orders grew nearly 20%, with all four franchises growing double-digits.

Repligen posted Q4 2024 revenue of $168 million, up 1% year-over-year. Adjusted EPS was $0.44, down from $0.48 in Q4 2023. The company reported a GAAP net loss of $34 million due to restructuring costs, but adjusted net income reached $25 million. Order growth in CDMO and capital equipment segments drove optimism for 2025.

Repligen reported a strong third quarter with a 10% increase in revenue compared to the previous year. The company saw growth in CDMO and equipment sales, as well as record sales in new modalities. Full year revenue guidance was narrowed to $630-$639 million.

Repligen reported Q2 2024 revenue of $154 million, slightly below the $159 million reported in Q2 2023. The company achieved its year-to-date sales target with first-half revenue of $305 million. The company is narrowing its revenue guidance for fiscal year 2024 but adjusted EPS guidance remains unchanged.

Repligen reported a solid first quarter with a revenue of $151 million. The company saw growth in the Filtration franchise excluding COVID and continued strength from new modality customers. The company is maintaining its adjusted 2024 financial guidance, expecting orders to pick up during the second half of the year.

Repligen reported Q4 2023 revenue of $155.7 million, compared to $186.8 million for 2022. The company's book-to-bill ratio was 1.03 for the quarter. The company is optimistic that its markets will improve as it advances through 2024, with growth accelerating in the second half of the year.

Repligen reported a decrease in total revenue to $141.2 million compared to $200.7 million in Q3 2022. The company saw positive signs of recovery with a book-to-bill ratio of 1.07. They narrowed their full year revenue guidance to $635-$645 million.

Repligen reported a decrease in revenue for Q2 2023, with total revenue at $159.2 million, a 23.3% decrease year-over-year. The company adjusted its full-year revenue guidance to $635-$665 million. The decline was primarily due to headwinds in Filtration. Despite these challenges, the Analytics, Proteins, and Chromatography franchises saw growth. The company remains optimistic about managing through these headwinds by the end of the year.

Repligen reported a 12% decrease in revenue for Q1 2023, totaling $182.7 million compared to $206.4 million in Q1 2022. The company's gross margin was 55.2%, and net income was $28.8 million, a 39% decrease year-over-year. Despite the decline, Repligen is optimistic about long-term growth in bioprocessing, supported by strategic acquisitions and new product development.

Repligen Corporation reported fourth-quarter revenue of $186.8 million, representing a 4% year-over-year organic growth (5% at constant currency). The base business demonstrated strong growth, with a 35% increase during the quarter. GAAP earnings per share increased to $0.85, while adjusted earnings per share were $0.68.

Repligen reported revenue of $200.7 million for Q3 2022, a 13% increase year-over-year, with base business growth of 29%. The company updated its full-year 2022 financial guidance, reflecting confidence in continued growth.

Repligen reported a record revenue of $207.6 million for Q2 2022, representing a 27% year-over-year increase as reported and 32% at constant currency. The company's strong organic revenue growth of 29% and base business growth of 41% drove the results. Repligen raised its full-year revenue guidance to $790-$810 million.

Repligen Corporation reported record revenue of $206.4 million for Q1 2022, a 45% increase year-over-year, with organic growth of 44%. The company's base business grew by 37%, while COVID-related sales accounted for 26% of revenue. Increased guidance for full year non-COVID business performance was provided.

Repligen reported record revenue of $186.5 million for Q4 2021, a 72% increase year-over-year. GAAP EPS increased to $0.50, while adjusted EPS reached $0.81. The company's strong performance was attributed to accelerated demand for its products and the impact of recent acquisitions.

Repligen reported record revenue of $178.2 million for Q3 2021, representing an 89% year-over-year increase and 77% organic growth. The company's base business grew by 49%, with COVID programs accounting for approximately 27% of revenue. The acquisition of Avitide Inc. was completed, strengthening the Proteins franchise. Full-year revenue guidance was raised to $655-$665 million.

Repligen reported a strong second quarter of 2021, with revenue reaching $163.0 million, an 86% increase year-over-year. The company's base business grew 35% year-over-year, and COVID-related sales accounted for 27% of revenue. Gross and operating margins also increased, and the company updated its full-year financial guidance to reflect continued momentum.

Repligen Corporation reported strong first-quarter results with an 88% increase in revenue to $142.8 million, driven by COVID-related demand, base business growth, and contributions from acquisitions. The company updated its full-year financial guidance to reflect expectations for operating margin expansion and organic revenue growth.

Repligen reported a strong fourth quarter in 2020, with revenue increasing by 56% year-over-year to $108.6 million and organic growth of 47%. GAAP EPS was $0.36, and adjusted EPS was $0.52. The company's performance was driven by sales into COVID vaccine and therapeutic accounts, as well as robust growth across all franchises.

Repligen reported a strong third quarter in 2020, achieving a record quarterly revenue of $94.1 million, driven by a 35% year-over-year growth and a 31% organic growth. COVID programs accounted for approximately 14% of revenue during the quarter, contributing to approximately 55% of revenue growth. The company also updated its full-year 2020 financial guidance, raising revenue expectations to $348-$352 million.

Repligen Corporation reported strong financial results for the second quarter of 2020, with record quarterly revenue of $87.5 million, a 24% increase year-over-year. The company also raised its full-year revenue guidance to $332-$340 million, reflecting expected organic growth of 18%-21%.

Repligen Corporation reported a 25% year-over-year increase in revenue, reaching $76.1 million in Q1 2020. The company's GAAP earnings per share increased to $0.18, and adjusted EPS grew to $0.32. The company is maintaining its full year revenue guidance.

Repligen Corporation reported a strong fourth quarter in 2019, with a 34% increase in revenue to $69.5 million and adjusted EPS increasing to $0.20. The company's organic revenue growth was 21% for the quarter. The company is optimistic about 2020.